Managing Myeloma: Where We Are, Where We’re Going, and Where We SHOULD Be Going (Time to Choose Sides!)
Release date: January 15, 2021
Expiration date: January 15, 2022
Estimated time to complete activity: 2 hours
In the last 17 years, clinicians and patients have witnessed significant advances in multiple myeloma (MM) management, with the development of new strategies for establishing diagnosis, assessing prognosis, monitoring minimal residual disease (MRD), and delivering supportive care. Even more remarkably, in this time 14 new drugs have been approved by the US Food and Drug Administration for use in MM.
This expansion of MM management options brings both opportunities and challenges for oncology HCPs. Furthermore, the rapidity with which clinical data relating to MM therapy is evolving and emerging all but ensures that the MM treatment paradigm will continue to change significantly in the near future.
This activity follows a debate format and features audience polling relating to the proffered arguments, as well as panel discussions.
Jointly provided by
Support for this activity has been provided through educational grants from Adaptive Biotechnologies Corporation; Amgen, Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics, Inc.; and Oncopeptides.
The joint sponsors also wish to thank CURE and Targeted Oncology for their support.
This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with MM.
Upon successful completion of this educational activity, participants should be better able to:
- Evaluate emerging data regarding the approach to maintenance therapy based on MRD status
- Describe the options available to patients who have relapsed from or are resistant to multiple prior therapies
- Incorporate the use of novel agent/monoclonal antibody–based regimens for newly diagnosed or relapsed/refractory MM patients based on currently available evidence
Hearn Jay Cho, MD, PhD—Program Co-Chair
Chief Medical Officer
Multiple Myeloma Research Foundation
Icahn School of Medicine at Mount Sinai
New York, New York
Paul G. Richardson, MD—Program Co-Chair
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
A. Keith Stewart, MBChB—Program Co-Chair
Professor of Medicine
University of Toronto
Princess Margaret Cancer Centre
Vice President Cancer
University Health Network
Toronto, Ontario, Canada
Adam D. Cohen, MD
Associate Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Suzanne Lentzsch, MD, PhD
Professor of Medicine
Columbia University Medical College
College of Physicians and Surgeons
Director, Multiple Myeloma and Amyloidosis Service
New York Presbyterian Hospital/Columbia University Medical Center
New York, New York
David S. Siegel, MD, PhD
Founding Director, Institute for Multiple Myeloma
Hackensack Meridian Health Center for Discovery & Innovation
Chief, Multiple Myeloma Division
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
How to Participate in This Activity and Obtain CME Credit
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 75% or greater) and program evaluation. Certificates can be printed immediately.
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Hearn Jay Cho, MD, PhD, has disclosed the following relevant financial relationships:
Research Grant: Bristol Myers Squibb/Celgene, Takeda
Paul G. Richardson, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Celgene, Janssen, Karyopharm, Oncopeptides, Sanofi, Secura Bio, Takeda
Research Grant: Bristol Myers Squibb, Celgene, Oncopeptides, Takeda
A. Keith Stewart, MBChB, has disclosed the following relevant financial relationships:
Consultant/Advisor: Amgen, Bristol Myers Squibb, Celgene
Adam D. Cohen, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: AstraZeneca, Bristol Myers Squibb/Celgene, Genentech, GlaxoSmithKline, Janssen, Seattle Genetics, Takeda
Research Grant: Novartis
Suzanne Lentzsch, MD, PhD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Caelum Bioscience, Celularity, Janssen, Sorrento
Research Grant: Karyopharm, Sanofi
Royalties/Patents: Caelum Bioscience
Stock Ownership: Caelum Bioscience
David S. Siegel, MD, PhD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Bristol Myers Squibb, Celularity, Janssen, Karyopharm, Takeda
Speakers Bureau: Bristol Myers Squibb, GlaxoSmithKline, Janssen, Takeda
Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Multiple Myeloma Research Foundation
Mary DeRome, Director of Medical Communications and Education, has disclosed no relevant financial relationships.
Anne Quinn Young, MPH, Vice President of Development & Strategic Partnerships, has disclosed no relevant financial relationships.
Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Kristen Petro Slade, Director of Operations, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.
Karen Tenaglia, Project Manager, has disclosed no relevant financial relationships.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Adaptive Biotechnologies Corporation; Amgen, Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics, Inc.; and Oncopeptides do not recommend the use of any agent outside the labeled indications.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Adaptive Biotechnologies Corporation; Adaptive Biotechnologies Corporation; Amgen, Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics, Inc.; and Oncopeptides. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
CME credit for this activity is provided by Penn State College of Medicine. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to Penn State College of Medicine so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. Penn State College of Medicine or RedMedEd may use the information you provide on this site to contact you about your CME credit or other relevant educational activities. For more information, contact ContinuingEd@hmc.psu.edu or firstname.lastname@example.org.
- A computer with an Internet connection
- Internet browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards–compliant browser
- Additional software: Adobe Flash Player and/or an HTML 5–capable browser may be required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
© 2021. This CME-certified program is held as copyrighted by Penn State College of Medicine, MMRF, and RedMedEd. Through this notice, Penn State College of Medicine, MMRF, and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.
For questions regarding CME credit, please contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6656-21-T.
For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or email@example.com.